A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides

• Status: Completed
• Trial end date: 2016-04-26
• Target enrollment: 0
• Participant gender: All

Summary

This is a safety and efficacy study of onabotulinumtoxinA in subjects with forehead and glabellar facial rhytides (frown lines).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Moderate to severe forehead and glabellar lines

• Willing to have facial photos taken

Exclusion Criteria:

• Prior exposure to botulinum toxin of any serotype for any indication

• Anticipated need for treatment with botulinum toxin of any serotype for any indication during the study, other than study treatment

• Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis

• Any facial resurfacing laser or light treatment, microdermabrasion, or superficial peels in the past 3 months

• Any medium depth or deep depth facial chemical peels; facial skin resurfacing; or permanent facial make-up in the past 6 months

• Any nonpermanent soft tissue fillers, or treatment with oral retinoids in the past year

• Prior face lift, thread lift, eyebrow lift, or related procedures (eg, eyelid and/or eyebrow surgery)

• Prior facial treatment with permanent soft tissue fillers, synthetic implants (eg, Gore-Tex®), and/or fat transplantation